| Dr Douglas G Harrison, MD | |
|
2020 W 16th St, Safford, AZ 85546-4026 | |
| (928) 424-4444 | |
| (928) 424-4446 |
| Full Name | Dr Douglas G Harrison |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 24 Years |
| Location | 2020 W 16th St, Safford, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720065253 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 053918 (Georgia) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 41204 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mt Graham Regional Medical Center Inc | 6204822364 | 26 |
News Archive
Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.
As a medical emergency caused by severe cardiovascular diseases, myocardial infarction (MI) can inflict permanent and life-threatening damage to the heart.
By applying a systems biology approach, a recent bioRxiv* preprint research paper by scientists from the Icahn School of Medicine at Mount Sinai in New York unveils interactions between the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and p38 mitogen-activated protein kinase (MAPK) pathway responsible for regulating the expression of crucial inflammatory mediators in human lung epithelial cells.
Contractors paid tens of millions of taxpayer dollars to detect fraudulent Medicare claims are using inaccurate and inconsistent data that makes it extremely difficult to catch bogus bills submitted by crooks, according to an inspector general's report released Monday.
Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the receipt of three grants totaling more than $733,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.
› Verified 9 days ago
| Entity Name | Mt Graham Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275588345 PECOS PAC ID: 6204822364 Enrollment ID: O20040423000105 |
News Archive
Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.
As a medical emergency caused by severe cardiovascular diseases, myocardial infarction (MI) can inflict permanent and life-threatening damage to the heart.
By applying a systems biology approach, a recent bioRxiv* preprint research paper by scientists from the Icahn School of Medicine at Mount Sinai in New York unveils interactions between the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and p38 mitogen-activated protein kinase (MAPK) pathway responsible for regulating the expression of crucial inflammatory mediators in human lung epithelial cells.
Contractors paid tens of millions of taxpayer dollars to detect fraudulent Medicare claims are using inaccurate and inconsistent data that makes it extremely difficult to catch bogus bills submitted by crooks, according to an inspector general's report released Monday.
Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the receipt of three grants totaling more than $733,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.
› Verified 9 days ago
| Entity Name | Mt Graham Regional Medical Center Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1275588345 PECOS PAC ID: 6204822364 Enrollment ID: O20201016000847 |
News Archive
Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.
As a medical emergency caused by severe cardiovascular diseases, myocardial infarction (MI) can inflict permanent and life-threatening damage to the heart.
By applying a systems biology approach, a recent bioRxiv* preprint research paper by scientists from the Icahn School of Medicine at Mount Sinai in New York unveils interactions between the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and p38 mitogen-activated protein kinase (MAPK) pathway responsible for regulating the expression of crucial inflammatory mediators in human lung epithelial cells.
Contractors paid tens of millions of taxpayer dollars to detect fraudulent Medicare claims are using inaccurate and inconsistent data that makes it extremely difficult to catch bogus bills submitted by crooks, according to an inspector general's report released Monday.
Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the receipt of three grants totaling more than $733,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Douglas G Harrison, MD Po Box 2660, Thatcher, AZ 85552-2660 Ph: (928) 424-4444 | Dr Douglas G Harrison, MD 2020 W 16th St, Safford, AZ 85546-4026 Ph: (928) 424-4444 |
News Archive
Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.
As a medical emergency caused by severe cardiovascular diseases, myocardial infarction (MI) can inflict permanent and life-threatening damage to the heart.
By applying a systems biology approach, a recent bioRxiv* preprint research paper by scientists from the Icahn School of Medicine at Mount Sinai in New York unveils interactions between the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and p38 mitogen-activated protein kinase (MAPK) pathway responsible for regulating the expression of crucial inflammatory mediators in human lung epithelial cells.
Contractors paid tens of millions of taxpayer dollars to detect fraudulent Medicare claims are using inaccurate and inconsistent data that makes it extremely difficult to catch bogus bills submitted by crooks, according to an inspector general's report released Monday.
Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the receipt of three grants totaling more than $733,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.
› Verified 9 days ago